$6.56
-0.49[-6.95%]
At close: Apr 18
$6.56
0[0.00%]
After Hours: 4:43PM EDT
Larimar Therapeutics
(NASDAQ:LRMR)Larimar Therapeutics Stock (NASDAQ:LRMR), Analyst Ratings, Price Targets, Predictions
Larimar Therapeutics Inc has a consensus price target of $14.8, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Leerink Partners, JMP Securities, and JMP Securities on April 3, 2024, March 15, 2024, and March 12, 2024. With an average price target of $25 between Leerink Partners, JMP Securities, and JMP Securities, there's an implied 281.10% upside for Larimar Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
JMP Securities
Citigroup
Guggenheim
William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Larimar Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 281.1% | Leerink Partners | Joori Park | → $25 | Initiates | → Outperform | Get Alert |
| 03/15/2024 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 281.1% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/12/2024 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 281.1% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2024 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 52.44% | Citigroup | Samantha Semenkow | $4.5 → $10 | Maintains | Buy | Get Alert |
| 02/13/2024 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 281.1% | JMP Securities | Jonathan Wolleben | $17 → $25 | Maintains | Market Outperform | Get Alert |
| 11/17/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | -31.4% | Citigroup | Samantha Semenkow | → $4.5 | Upgrade | Neutral → Buy | Get Alert |
| 08/15/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 159.15% | JMP Securities | Jonathan Wolleben | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/18/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | -31.4% | Citigroup | Samantha Semenkow | $7 → $4.5 | Maintains | Neutral | Get Alert |
| 05/17/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 113.41% | Guggenheim | Yatin Suneja | $12 → $14 | Maintains | Buy | Get Alert |
| 05/16/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 128.66% | JMP Securities | Jonathan Wolleben | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/15/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 6.71% | Citigroup | Samantha Semenkow | → $7 | Maintains | Neutral | Get Alert |
| 03/15/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 82.93% | Guggenheim | Yatin Suneja | → $12 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 128.66% | JMP Securities | Jonathan Wolleben | $15 → $15 | Maintains | Market Outperform | Get Alert |
| 03/01/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 128.66% | JMP Securities | Jonathan Wolleben | → $15 | Maintains | Market Outperform | Get Alert |
| 01/24/2023 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 143.9% | JMP Securities | Jonathan Wolleben | $16 → $16 | Maintains | Market Outperform | Get Alert |
| 12/13/2022 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | -39.02% | Citigroup | Samantha Semenkow | → $4 | Initiates | → Neutral | Get Alert |
| 10/19/2022 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 82.93% | Guggenheim | Yatin Suneja | → $12 | Initiates | → Buy | Get Alert |
| 09/19/2022 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | 143.9% | JMP Securities | Jonathan Wolleben | $10 → $16 | Maintains | Market Outperform | Get Alert |
| 09/19/2022 | LRMR | Buy Now | Larimar Therapeutics | $6.56 | — | William Blair | Myles Minter | — | Upgrade | Market Perform → Outperform | Get Alert |
FAQ
What is the target price for Larimar Therapeutics (LRMR)?
The latest price target for Larimar Therapeutics (NASDAQ: LRMR) was reported by Leerink Partners on April 3, 2024. The analyst firm set a price target for $25.00 expecting LRMR to rise to within 12 months (a possible 281.10% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Larimar Therapeutics (LRMR)?
The latest analyst rating for Larimar Therapeutics (NASDAQ: LRMR) was provided by Leerink Partners, and Larimar Therapeutics initiated their outperform rating.
When was the last upgrade for Larimar Therapeutics (LRMR)?
The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.
When was the last downgrade for Larimar Therapeutics (LRMR)?
The last downgrade for Larimar Therapeutics Inc happened on February 15, 2022 when William Blair changed their price target from N/A to N/A for Larimar Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Larimar Therapeutics (LRMR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Larimar Therapeutics (LRMR) correct?
While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a initiated with a price target of $0.00 to $25.00. The current price Larimar Therapeutics (LRMR) is trading at is $6.56, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.